Cheshire Veterinary Dermatology Ltd 16173513 false 2025-01-09 2026-01-31 2026-01-31 The principal activity of the company is veterinary services. Digita Accounts Production Advanced 6.30.9574.0 true true 16173513 2025-01-09 2026-01-31 16173513 2026-01-31 16173513 bus:OrdinaryShareClass1 2026-01-31 16173513 bus:OrdinaryShareClass2 2026-01-31 16173513 bus:OrdinaryShareClass3 2026-01-31 16173513 bus:OrdinaryShareClass4 2026-01-31 16173513 core:ProvisionsDeferredTax 2026-01-31 16173513 core:TaxLossesCarry-forwardsDeferredTax 2026-01-31 16173513 core:ShareCapital 2026-01-31 16173513 core:FinanceLeases core:CurrentFinancialInstruments 2026-01-31 16173513 core:FinanceLeases core:Non-currentFinancialInstruments 2026-01-31 16173513 core:CurrentFinancialInstruments 2026-01-31 16173513 core:CurrentFinancialInstruments core:WithinOneYear 2026-01-31 16173513 core:Non-currentFinancialInstruments 2026-01-31 16173513 core:Non-currentFinancialInstruments core:AfterOneYear 2026-01-31 16173513 core:FurnitureFittingsToolsEquipment 2026-01-31 16173513 core:LandBuildings 2026-01-31 16173513 bus:SmallEntities 2025-01-09 2026-01-31 16173513 bus:AuditExemptWithAccountantsReport 2025-01-09 2026-01-31 16173513 bus:FilletedAccounts 2025-01-09 2026-01-31 16173513 bus:SmallCompaniesRegimeForAccounts 2025-01-09 2026-01-31 16173513 bus:RegisteredOffice 2025-01-09 2026-01-31 16173513 bus:Director1 2025-01-09 2026-01-31 16173513 bus:Director2 2025-01-09 2026-01-31 16173513 bus:OrdinaryShareClass1 2025-01-09 2026-01-31 16173513 bus:OrdinaryShareClass2 2025-01-09 2026-01-31 16173513 bus:OrdinaryShareClass3 2025-01-09 2026-01-31 16173513 bus:OrdinaryShareClass4 2025-01-09 2026-01-31 16173513 bus:PrivateLimitedCompanyLtd 2025-01-09 2026-01-31 16173513 bus:Agent1 2025-01-09 2026-01-31 16173513 core:FurnitureFittingsToolsEquipment 2025-01-09 2026-01-31 16173513 core:LandBuildings 2025-01-09 2026-01-31 16173513 core:KeyManagementPersonnel 2025-01-09 2026-01-31 16173513 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2025-01-09 2026-01-31 16173513 countries:EnglandWales 2025-01-09 2026-01-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 16173513

Prepared for the registrar

Cheshire Veterinary Dermatology Ltd

Annual Report and Unaudited Financial Statements

for the Period from 9 January 2025 to 31 January 2026

 

Cheshire Veterinary Dermatology Ltd

Contents

Company Information

1

Balance Sheet

2 to 3

Notes to the Unaudited Financial Statements

4 to 10

 

Cheshire Veterinary Dermatology Ltd

Company Information

Directors

I Segboer

B Pickavance

Registered office

Unit 5 & 6 Gadbrook Business Centre
Rudheath
Northwich
Cheshire
CW9 7TN

Accountants

Hazlewoods LLP Staverton Court
Staverton
Cheltenham
GL51 0UX

 

Cheshire Veterinary Dermatology Ltd

(Registration number: 16173513)
Balance Sheet as at 31 January 2026

Note

2026
£

Fixed assets

 

Tangible assets

4

407,082

Current assets

 

Stocks

5,556

Debtors

5

32,113

Cash at bank and in hand

 

133,538

 

171,207

Creditors: Amounts falling due within one year

6

(178,932)

Net current liabilities

 

(7,725)

Total assets less current liabilities

 

399,357

Creditors: Amounts falling due after more than one year

6

(366,343)

Deferred tax liabilities

7

(11,930)

Net assets

 

21,084

Capital and reserves

 

Called up share capital

9

120

Retained earnings

20,964

Shareholders' funds

 

21,084

For the financial period ending 31 January 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

 

Cheshire Veterinary Dermatology Ltd

(Registration number: 16173513)
Balance Sheet as at 31 January 2026

Approved and authorised by the Board on 19 June 2026 and signed on its behalf by:
 


I Segboer
Director


B Pickavance
Director

 

Cheshire Veterinary Dermatology Ltd

Notes to the Unaudited Financial Statements for the Period from 9 January 2025 to 31 January 2026

 

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Unit 5 & 6 Gadbrook Business Centre
Rudheath
Northwich
Cheshire
CW9 7TN

 

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except for, where disclosed in these accounting policies, certain items that are shown at fair value.

The presentational currency of the financial statements is Pounds Sterling, being the functional currency of the primary economic environment in which the company operates. Monetary amounts in these financial statements are rounded to the nearest Pound.

Going concern

After reviewing the company's forecasts and projections, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The company therefore continues to adopt the going concern basis in preparing its financial statements.

Critical accounting judgements and key sources of estimation uncertainty
In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.
 

Judgements

No significant judgements have been made by management in preparing these financial statements.

 

Cheshire Veterinary Dermatology Ltd

Notes to the Unaudited Financial Statements for the Period from 9 January 2025 to 31 January 2026

Key sources of estimation uncertainty

No key sources of estimation uncertainty have been identified by management in preparing these financial statements other than those detailed in these accounting policies.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts and after eliminating sales within the company.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rates prevailing on the initial transaction dates.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Tax

The tax expense for the period comprises and deferred tax. Tax is recognised in the profit and loss account, except that a charge attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

Deferred income tax is recognised on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements and on unused tax losses or tax credits in the company. Deferred income tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Leasehold property

straight line over 10 years

Furniture, fittings and equipment

10% & 25% written down value

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

 

Cheshire Veterinary Dermatology Ltd

Notes to the Unaudited Financial Statements for the Period from 9 January 2025 to 31 January 2026

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. All trade debtors are repayable within one year and hence are included at the undiscounted cost of cash expected to be received. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the debtors.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and all are repayable within one year and hence are included at the undiscounted amount of cash expected to be paid.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

 

Cheshire Veterinary Dermatology Ltd

Notes to the Unaudited Financial Statements for the Period from 9 January 2025 to 31 January 2026

Financial instruments


Classification
Financial instruments are classified and accounted for according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Where shares are issued, any component that creates a financial liability of the company is presented as a liability on the balance sheet. The corresponding dividends relating to the liability component are charged as interest expenses in the profit and loss account.


Recognition and measurement
All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.


Impairment
Assets, other than those measured at fair value, are assessed for indicators of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss as described below.

A non financial asset is impaired where there is objective evidence that, as a result of one or more events that occurred after initial recognition, the estimated recoverable value of the asset has been reduced. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use.

 

3

Staff numbers

The average number of persons employed by the company (including directors) during the period, was 2.

 

4

Tangible assets

Leasehold property
£

Furniture, fittings and equipment
 £

Total
£

Cost

Additions

203,564

236,146

439,710

At 31 January 2026

203,564

236,146

439,710

Depreciation

Charge for the

10,714

21,914

32,628

At 31 January 2026

10,714

21,914

32,628

Carrying amount

At 31 January 2026

192,850

214,232

407,082

 

Cheshire Veterinary Dermatology Ltd

Notes to the Unaudited Financial Statements for the Period from 9 January 2025 to 31 January 2026

 

5

Debtors

2026
£

Trade debtors

23,830

Prepayments

3,033

Other debtors

5,250

32,113

 

6

Creditors

Note

2026
£

Due within one year

 

Loans and borrowings

8

145,399

Trade creditors

 

3,036

Taxation and social security

 

16,420

Accruals and deferred income

 

14,077

 

178,932

Note

2026
£

Due after one year

 

Loans and borrowings

8

366,343

 

Cheshire Veterinary Dermatology Ltd

Notes to the Unaudited Financial Statements for the Period from 9 January 2025 to 31 January 2026

 

7

Deferred tax

Deferred tax assets and liabilities

2026

Asset
£

Liability
£

Fixed asset timing differences

-

70,889

Losses and other deductions

(58,959)

-

(58,959)

70,889

 

8

Loans and borrowings

Current loans and borrowings

2026
£

Bank borrowings

14,000

Hire purchase liabilities

31,472

Other borrowings

99,927

145,399

Non-current loans and borrowings

2026
£

Bank borrowings

250,167

Hire purchase liabilities

116,176

366,343

 

9

Share capital

Allotted, called up and fully paid shares

 

31 January 2026

 

No.

£

Ordinary A shares of £1 each

54

54

Ordinary B shares of £1 each

54

54

Ordinary C shares of £1 each

6

6

Ordinary D shares of £1 each

6

6

 

120

120

On 5 September 2025, 2 Ordinary shares were reclassified as 1 Ordinary A share and 1 Ordinary B share.

On 5 September 2025, 53 Ordinary A shares, 53 Ordinary B shares, 6 Ordinary C shares, and 6 Ordinary D shares were allotted.

The different classes of shares referred to above carry separate rights to dividends, but in all other significant respects, rank pari passu.

 

Cheshire Veterinary Dermatology Ltd

Notes to the Unaudited Financial Statements for the Period from 9 January 2025 to 31 January 2026

 

10

Related party transactions

Key management personnel

Key management personnel are considered to be the directors of the company.

Summary of transactions with key management

As at the balance sheet date, the company owed the directors' £99,927. This amount is included in other borrowings. There are no fixed repayment terms and interest is charged at 7.5%.